Vivet Therapeutics
http://www.vivet-therapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vivet Therapeutics
How Handl Was 'Built To Buy' By UCB
UCB has been looking to go deep into the gene therapy space for some time, CSO Dhaval Patel tells Scrip, saying that instead of treating symptoms, "you should be going for a cure."
J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A.
J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A.
Interview: Pfizer's Smith On Building A Gene Therapy Business
Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy